NextPoint Therapeutics develops precision immuno-oncology therapies targeting the B7-H7/HHLA2 immune checkpoint to reactivate exhausted T and NK cells in solid tumors. This approach aims to provide effective treatment options for cancer patients who do not respond to existing PD-1/L1 inhibitors, enhancing therapeutic outcomes through biomarker-driven patient selection.
Funding
$178.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CCFounders
Product
Problem
Many solid tumors do not respond to existing immunotherapies like PD-1/L1 inhibitors, leaving a significant unmet need for effective treatment options. The B7-H7/HHLA2 pathway can inhibit anti-tumor immune responses, providing a potential target for novel cancer therapeutics.
Solution
NextPoint Therapeutics develops precision immuno-oncology therapies that target the B7-H7/HHLA2 immune checkpoint to reactivate exhausted T and NK cells within solid tumors. Their approach utilizes a defined clinical biomarker to identify patient populations most likely to respond to B7-H7-directed therapies, including those who do not benefit from PD-1/L1 inhibitors. NextPoint is advancing a pipeline of first-in-class assets, including an antibody-drug conjugate (ADC), a T-cell engager, and a multi-functional checkpoint inhibitor, to maximize opportunities for immunomodulation and tumor-targeting through the B7-H7 axis. These therapies aim to combine direct tumor killing with immunomodulation.
Target Audience
The primary target audience includes cancer patients with solid tumors expressing the B7-H7/HHLA2 biomarker, particularly those who are unresponsive to existing PD-1/L1 inhibitors, as well as the physicians treating them.
Features
- NPX887: A therapeutic targeting HHLA2 currently in Phase 1a/b clinical trials
- NPX267: A therapeutic targeting KIR3DL3
- NPX372: A B7-H7xCD3 T cell engager
- B7-H7-ADC: An antibody-drug conjugate utilizing proprietary linker technology
- Exploitation of the B7-H7 axis for both immunomodulation and tumor-targeting
- Biomarker-driven patient selection to enhance therapeutic outcomes